(GH) Guardant Health - Ratings and Ratios

Guardant Health, Inc. (NASDAQ:GH) is a leader in precision oncology, specializing in innovative blood and tissue-based tests and datasets for cancer treatment and research. The companys portfolio includes Guardant360, a comprehensive genetic testing panel, and Guardant360 LDT, which analyzes over 730 genes and supports all guideline-recommended biomarkers. Other key offerings include Guardant360 CDx, a liquid biopsy test; Guardant360 Response, a blood-only liquid biopsy; Guardant360 TissueNext, an AI-enhanced tissue-based test; and GuardantINFINITY, which provides molecular insights for cancer research and therapy development. Additionally, GuardantConnect is a software-based solution connecting patients with actionable test results to relevant clinical studies. The company also offers GuardantOMNI for advanced-stage cancer and GuardantINFORM, an in-silico platform for studying tumor evolution and treatment resistance.

Guardant Health provides a range of development services, including companion diagnostic development, clinical study setup, and regulatory support. It also offers the Shield Test for screening, Guardant Reveal for monitoring early-stage cancer patients, and the Smart Liquid Biopsy Platform. Founded in 2011 and headquartered in Palo Alto, California, the company has established itself as a pioneer in liquid biopsy technology and precision oncology solutions.

Ticker Symbol: GH Exchange: NASDAQ Type: Common Stock Country Origin: United States GICS Sub Industry: Health Care Services

Based on the provided technical and fundamental data, here is a 3-month forecast for Guardant Health (NASDAQ:GH): - Technical Outlook: The stock is currently trading at $48.30, with a 20-day SMA of $43.63 and a 50-day SMA of $43.67, indicating short-term bullish momentum. The 200-day SMA of $34.09 suggests long-term upside potential. ATR of 2.94 signals moderate volatility. - Fundamental Outlook: With a market cap of $5.4 billion and a P/S ratio of 7.31, the company is valued at a premium, reflecting its growth prospects. The P/B ratio of 55.67 and RoE of 312.48 highlight strong equity returns. However, the absence of P/E ratios and high valuation multiples warrant caution. - 3-Month Forecast: Expect continued upward momentum in the short term, driven by strong technical indicators. Longer-term trends will depend on the companys ability to maintain growth and justify its premium valuation. Volatility is expected to remain manageable, with support from the 50-day SMA.